Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

jefferson.edu

Total trials

161

Active

9

Phase 3

6

Total enrollment

10,932

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Sunitinib2
Valproic Acid1
Sunitinib Malate1
Sunitinib Malate + Valproic Acid1
Ibrutinib1
Obinutuzumab1
Linaclotide1

Next readouts

  • 2026-06-30
  • 2026-09-11
  • 2026-12-31

Top conditions

  • Prostate Cancer11
  • Breast Cancer6
  • Malignant Neoplasm5
  • Head and Neck Cancer5
  • Breast Carcinoma5
  • Non-Hodgkin's Lymphoma4
  • Aplastic Anemia4
  • Larynx4

Frequently asked questions about Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

How many clinical trials does Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University have on ClinicalTrials.gov?
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University is listed as the lead sponsor on 161 clinical trials in ClinicalTrials.gov, 9 of which are currently active (recruiting, enrolling, or ongoing).
How many of Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University's trials are in Phase 3?
6 of Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University focus on?
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Breast Cancer, Malignant Neoplasm, Head and Neck Cancer, Breast Carcinoma.
When are Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University's next clinical trial readouts?
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University has 3 upcoming primary-completion readouts tracked here; the soonest is “Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer”, expected around 2026-06-30.